🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 9 of 151

  1. AP-SA02

    Armata Pharmaceuticals

    Bacteremia

    phase 2 mab completed

    1 trial

  2. AP02 High, AP02 Low, AP02 Placebo

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  3. AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  4. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  5. AP707, Placebo

    Lacuna Pharma Pty Ltd

    Borderline personality disorder

    phase 2 small molecule active

    1 trial

  6. APD334

    Arena Pharmaceutical Enterprises Limited

    Primary Biliary Cholangitis

    phase 2 small molecule terminated

    1 trial

  7. APD334

    Arena Pharmaceutical Enterprises Limited

    Pyoderma Gangrenosum

    phase 2 small molecule terminated

    1 trial

  8. APD811

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 2 small molecule completed

    1 trial

  9. APG777

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    3 trials

  10. APG777, Placebo

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  11. APL-2

    Apellis Europe B.V.

    IgA Nephropathy

    phase 2 small molecule completed

    1 trial

  12. APL-2

    Apellis Europe B.V.

    Warm Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  13. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  14. APL-9

    Apellis Europe B.V.

    COVID

    phase 2 small molecule completed

    1 trial

  15. APO010

    Allarity Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  16. APR-246

    Aprea Therapeutics

    Melanoma

    phase 2 small molecule terminated

    1 trial

  17. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome

    phase 2 small molecule completed

    1 trial

  18. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  19. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  20. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome With Gene Mutation

    phase 2 small molecule active

    1 trial

  21. APR-246

    Aprea Therapeutics

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  22. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea Therapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  23. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea Therapeutics

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  24. APREPITANT, IDARUBICIN HYDROCHLORIDE, LEVOCARNITINE, CYCLOPHOSPHAMIDE, GRANISETRON, SALBUTAMOL, GANCICLOVIR, AMPHOTERICIN B, ALLOPURINOL, DARZALEX 1800 mg solution for injection, HUMAN FIBRINOGEN, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, VINCRISTINE SULFATE, PARACETAMOL, MONTELUKAST, FILGRASTIM, CYTARABINE, LEVOFLOXACIN, RASBURICASE, METHOTREXATE, HYDROCORTISONE, FOSCARNET, METHYLPREDNISOLONE SODIUM SUCCINATE, LENOGRASTIM, PEGASPARGASE, DEXAMETHASONE SODIUM PHOSPHATE, MICAFUNGIN, ACICLOVIR, CHLORPHENAMIN

    Fondazione Telethon ETS

    Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  25. APX005M

    Pyxis Oncology

    Melanoma

    phase 2 small molecule terminated

    1 trial

  26. ARB-001467

    Arbutus Biopharma Corp

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  27. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  28. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  29. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  30. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  31. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  32. ARC-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    2 trials

  33. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial

  34. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial

  35. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial

  36. ARCT-032

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 small molecule active

    2 trials

  37. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial

  38. ARCT-810

    Arcturus Therapeutics Holdings

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials

  39. ARCT-810

    Arcturus Therapeutics Holdings

    OTC Deficiency

    phase 2 mab active

    1 trial

  40. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  41. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial

  42. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  43. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  44. ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    Disc Medicine

    relapsed/refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  45. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  46. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  47. ARO-AAT

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  48. ARO-ALK7

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.